Results 161 to 170 of about 751,645 (378)

Viability of Pseudomonas aeruginosa [PDF]

Journal of Bacteriology, 1964
I Koumentakou, A Emmanouilidou-Arseni
openaire   +3 more sources

Elexacaftor–Tezacaftor–Ivacaftor Improves Sinonasal Outcomes in Young Children With Cystic Fibrosis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Severe chronic rhinosinusitis (CRS) is a near universal manifestation of cystic fibrosis. Elexacaftor/tezacaftor/ivacaftor (ETI) is an oral, small molecule, highly effective Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) corrector–potentiator drug.
Amanda L. Stapleton, Adam Kimple, Jennifer L. Goralski, Daniel M. Beswick, Anshika Gupta, Douglas A. Li, Barton F. Branstetter, S. Mehdi Nouraie, Amber D. Shaffer, Brent Senior, Anna C. Zemke   +10 more
wiley   +1 more source

Repurposing of Meropenem and Nadifloxacin for Treatment of Burn Patients? [PDF]

, 2009
The escalating number of multidrug resistant pathogens has demanded the swift development of new and potent antibiotics (ref. 2). Metallo-[beta]-lactamases (MBLs) continue to evolve, rendering the latest generation of carbapenem antibiotics useless (ref.
Christie E. Costa, James Spencer, Janice D. Thomas, Jeffrey H. Toney, Joseph G. Moloughney, Karla S. Bullon   +5 more
core   +1 more source

Beyond the Lung. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Sinonasal Disease in Children With Cystic Fibrosis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Elexacaftor/tezacaftor/ivacaftor (ETI) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) therapy that improves pulmonary function and chronic rhinosinusitis (CRS) in cystic fibrosis (CF) adults with at least one copy of the F508del CFTR mutation.
Margaux Petitjean, Alexia Letierce, Anne‐Sophie Bonnel, Philippe Reix, Eric Deneuville, Nathalie Stremler, Romain Luscan, Vincent Couloigner, Laurent Mely, Katia Bessaci, Guillaume Labbe, Christophe Marguet, Mairead Kelly‐Aubert, Fatiha Hassani, Isabelle Sermet‐Gaudelus, François Simon, the MODUL‐CF Study Group   +16 more
wiley   +1 more source

THE MALONIC DECARBOXYLASE OF PSEUDOMONAS AERUGINOSA [PDF]

, 1952
Clarke T. Gray
openalex   +1 more source

THE SARCOSINE OXIDASE IN ADAPTED AND UNADAPTED CULTURES OF A STRAIN OF PSEUDOMONAS AERUGINOSA [PDF]

, 1950
Frederick Bernheim
openalex   +1 more source

A Winogradsky-based culture system shows an association between microbial fermentation and cystic fibrosis exacerbation. [PDF]

, 2015
There is a poor understanding of how the physiology of polymicrobial communities in cystic fibrosis (CF) lungs contributes to pulmonary exacerbations and lung function decline.
Bailey, Barbara, Blake, Don, Conrad, Doug, Lim, Yan-Wei, Mienardi, Simone, Quinn, Robert A, Rohwer, Forest, Salamon, Peter, Sanchez, Savannah E, Whiteson, Katrine   +9 more
core   +1 more source

Epidemiological Fingerprinting of Pseudomonas aeruginosa by the Production of and Sensitivity to Pyocin and Bacteriophage [PDF]

, 1969
J. J. Farmer, Lloyd G. Herman
openalex   +2 more sources

FACTORS WHICH AFFECT THE OXIDATION OF BENZOIC ACID BY A STRAIN OF PSEUDOMONAS AERUGINOSA [PDF]

, 1953
Frederick Bernheim, William E. DeTurk
openalex   +1 more source

Non‐Amphiphilic Antimicrobial Polymers

Angewandte Chemie International Edition, Accepted Article.
Antimicrobial resistance (AMR) is a severe threat to modern health care and must be addressed to prevent millions of deaths in the coming decades. Antimicrobial polymers (APs) do not provoke resistances and are promising alternatives to conventional antibiotics. Classic APs possess an amphiphilic structure (cationic and hydrophobic). Herein we question
Alain M. Bapolisi, Anne-Catherine Lehnen, Martin Wolff, Jana Kramer, Sergio Kogikoski, René Steinbrecher, Nicole Michler, Andreas Kiesow, Ilko Bald, Martina Obry, Sebastian Kersting, Till Stensitzki, Henrike M. Müller-Werkmeister, Meike N. Leiske, Salvatore Chiantia, Matthias Hartlieb   +15 more
wiley   +1 more source